Related Experiment Video
Updated: Feb 15, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
The biology and management of non-small cell lung cancer
Roy S Herbst1, Daniel Morgensztern2, Chris Boshoff1,3
1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
Abstract:
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
Insights
Significant progress in non-small cell lung cancer (NSCLC) treatment has been made, yet survival rates, especially for metastatic disease, remain low. Further research into novel therapies and combinations is crucial for improved patient outcomes.
Area of Science:
- Oncology
- Translational Medicine
- Cancer Biology
Background:
- Non-small cell lung cancer (NSCLC) treatment has seen advancements over 20 years.
- Understanding of NSCLC biology and tumor progression has increased.
- Early detection and multimodal care strategies have improved.
Purpose of the Study:
- To review recent advancements in non-small cell lung cancer (NSCLC) treatment.
- To highlight the impact of targeted therapies and immunotherapy.
- To emphasize the need for continued research in NSCLC drug development.
Main Methods:
- Review of key advancements in NSCLC treatment over the past two decades.
- Analysis of the impact of small molecule tyrosine kinase inhibitors and immunotherapy.
- Assessment of current survival rates and challenges in metastatic NSCLC.
Main Results:
- Small molecule tyrosine kinase inhibitors and immunotherapy offer survival benefits in select NSCLC patients.
- Despite progress, overall cure and survival rates for NSCLC, particularly metastatic disease, remain suboptimal.
- Significant unmet needs persist in expanding treatment benefits to a wider patient population.
Conclusions:
- Continued research into novel drugs and combination therapies is essential for NSCLC.
- Improving outcomes for NSCLC requires expanding clinical benefit to more patients.
- Advancing NSCLC treatment necessitates a focus on overcoming limitations in metastatic settings.
Related Concept Videos
Lung Capacity
What is Conservation Biology?
Biological Effects of Radiation
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Cancer Cell Migration through Invadopodia

